Core Viewpoint - BGM Group Ltd. has received a notification from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 20-F for the fiscal year ended September 30, 2025 [1][2]. Compliance and Regulatory Actions - The company has 60 calendar days to submit a plan to Nasdaq to regain compliance, with a potential extension of up to 180 days if the plan is accepted [2]. - If the plan is not accepted, the company can appeal the decision to a Hearing Panel, but the notification does not immediately affect the listing of its class A ordinary shares [3]. Company Operations and Focus - BGM Group Ltd. focuses on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [5]. - In AI applications, the company utilizes advanced analytics and AI Agent technology to provide solutions for insurance companies, covering areas such as sales, underwriting, claims processing, and customer service [6]. - The biopharmaceutical division produces oxytetracycline API, crude heparin sodium, and licorice preparations, integrating AI-assisted decision-making to optimize supply chains and improve process efficiency [7].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shanghai Seer Intelligent Technology Co., Ltd. 上海仙工智能科技股份有限公司 (the "Company") (A joint stock company established in ...